Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990

Christopher M. McBride, Barry H. Levine, Yi Xia, Cornelia Bellamacina, Timothy Machajewski, Zhenhai Gao, Paul A. Renhowe, William Antonios-McCrea, Paul A. Barsanti, Kristin M. Brinner,

Journal of Medicinal Chemistry · 2014 · 28 citations · 7 references

DOIFull text

Open access

Concepts

Abstract

Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.

References

7